VANCOUVER, BC, June 7, 2023 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB)(OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that the results of its Annual General Meeting held on June 6, 2023. All resolutions set forth in the Information Circular were approved.
The following director nominees were re-elected to serve for the coming year:James Passin (99.08% FOR)Anthony Dutton (99.37% FOR)Craig Loverock (99.28% FOR)The following resolutions were also approved:Setting the number of Directors at three (99.41% in Favour)Re-appointing Dale Matheson Carr-Hilton LaBonte LLP, Chartered Professional Accountants asAuditor (99.60% in Favour)Re-approving the Company's Stock Option Plan (98.98% in Favour)A total of 28,747,103 common shares representing 19.44 % of the 147,841,627 common sharesentitled to vote were represented in person or by proxy at the meeting. Further details on thematters considered at the meeting can be found in Company's Information Circular dated May 2,2023, which is available under the Company's profile at www.sedar.com.The Company also announces that Dasha Enenko has resigned as Chief Financial Officer andCorporate Secretary to pursue other opportunities. James Passin will serve as Interim ChiefFinancial Officer and Interim Corporate Secretary until a permanent replacement is located.
About BioVaxys Technology Corp.
Based in Vancouver, BioVaxys Technology Corp. (www.biovaxys.com) is a British Columbiaregistered, clinical stage biotechnology company that is developing viral and oncology vaccineplatforms, as well as immuno-diagnostics. The Company is advancing vaccines for SARS-CoV-2,SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology, andis planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovariancancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of aT cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issuedUS patents, and multiple US and international patent applications related to its cancer vaccines,antiviral vaccines, and diagnostic technologies. BioVaxys common shares are listed on the CSEunder the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US(OTCQB: BVAXF).ON BEHALF OF THE BOARDSigned "James Passin"James Passin, CEO+1 646 452 7054Cautionary Statements Regarding Forward Looking InformationThis press release includes certain "forward-looking information" and "forward-looking statements"(collectively "forward-looking statements") within the meaning of applicable Canadian and UnitedStates securities legislation including the United States Private Securities Litigation Reform Act of1995. All statements, other than statements of historical fact, included herein, without limitation,statements relating the future operating or financial performance of the Company, are forwardlooking statements. Forward-looking statements are frequently, but not always, identified by wordssuch as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", andsimilar expressions, or statements that events, conditions, or results "will", "may", "could", or"should" occur or be achieved. Forward-looking statements in this news release relate to, amongother things, a potential listing of the Company on a US national stock exchange or completing acapital markets transaction. There can be no assurance that such statementswill prove to beaccurate, and actual results and future events could differ materially from those expressedor implied in such forward-looking statements.These forward-looking statements reflect the beliefs, opinions and projections on the date thestatements are made and are based upon a number of assumptions and estimates. With regardsto BioVaxys' business, there are a number of risks that could affect the development of itsbiotechnology products, including, without limitation, the need for additional capital to fund clinicaltrials, its lack of operating history, uncertainty about whether its products will complete the long,complex and expensive clinical trial and regulatory approval process for approval of new drugsnecessary for marketing approval, uncertainty about whether its autologous cell vaccineimmunotherapy can be developed to produce safe and effective products and, if so, whether itsvaccine products will be commercially accepted and profitable, the expenses, delays anduncertainties and complications typically encountered by development stage biopharmaceuticalbusinesses, financial and development obligations under license arrangements in order to protectits rights to its products and technologies, obtaining and protecting new intellectual property rightsand avoiding infringement to third parties and their dependence on manufacturing by thirdparties.The Company does not assume any obligation to update the forward-looking statements ofbeliefs, opinions, projections, or other factors, should they change, except as required by law.
Revolutionizing treatment delivery